Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Condition:   Pulmonary TB Interventions:   Drug: Delamanid + Bedaquiline + OPC-167832 10 mg;   Drug: Delamanid + Bedaquiline + OPC-167832 30 mg;   Drug: Delamanid + Bedaquiline + OPC-167832 90 mg;   Drug: RHEZ Sponsors:   Otsuka Pharmaceutical Development& Commercialization, Inc.;   Bill and Melinda Gates Foundation Not yet recruiting

Source: ClinicalTrials.gov - February 3, 2022 Category: Research Source Type: clinical trials